Caption Management LLC Buys New Position in Bruker Corporation $BRKR

Key Points

• Caption Management LLC acquired 20,000 shares of Bruker Corporation, valued at approximately $835,000, indicating growing institutional interest in the medical research company.
• Bruker's stock recently experienced a series of analyst downgrades, with target prices being reduced by firms such as Barclays and Goldman Sachs, reflecting a cautious outlook on the company's performance.
• The company announced a quarterly dividend of $0.05, which will be paid on October 3rd, contributing to an annualized dividend yield of 0.6%.

Caption Management LLC bought a new stake in Bruker Corporation (NASDAQ:BRKR - Free Report) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 20,000 shares of the medical research company's stock, valued at approximately $835,000.

Other institutional investors also recently made changes to their positions in the company. Pinnacle Bancorp Inc. acquired a new position in shares of Bruker in the 1st quarter valued at approximately $29,000. Allworth Financial LP raised its position in shares of Bruker by 92.4% in the 1st quarter. Allworth Financial LP now owns 758 shares of the medical research company's stock valued at $30,000 after purchasing an additional 364 shares in the last quarter. Caitong International Asset Management Co. Ltd raised its position in shares of Bruker by 1,354.5% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 800 shares of the medical research company's stock valued at $33,000 after purchasing an additional 745 shares in the last quarter. Annis Gardner Whiting Capital Advisors LLC acquired a new stake in shares of Bruker during the 1st quarter valued at approximately $42,000. Finally, MassMutual Private Wealth & Trust FSB raised its position in shares of Bruker by 274.9% during the 1st quarter. MassMutual Private Wealth & Trust FSB now owns 1,091 shares of the medical research company's stock valued at $46,000 after acquiring an additional 800 shares in the last quarter. 79.52% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other Bruker news, CEO Frank H. Laukien purchased 2,608 shares of the firm's stock in a transaction dated Friday, June 6th. The stock was bought at an average price of $38.36 per share, with a total value of $100,042.88. Following the completion of the purchase, the chief executive officer owned 38,462,171 shares in the company, valued at $1,475,408,879.56. This trade represents a 0.01% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 27.30% of the company's stock.

Analysts Set New Price Targets

Several research firms recently issued reports on BRKR. Barclays dropped their price target on Bruker from $46.00 to $43.00 and set an "overweight" rating on the stock in a research report on Monday, August 4th. Jefferies Financial Group set a $60.00 price target on Bruker and gave the company a "buy" rating in a research report on Monday, August 4th. UBS Group dropped their price target on Bruker from $57.00 to $45.00 and set a "neutral" rating on the stock in a research report on Thursday, May 8th. Wells Fargo & Company dropped their price target on Bruker from $60.00 to $50.00 and set an "overweight" rating on the stock in a research report on Tuesday, August 5th. Finally, The Goldman Sachs Group dropped their price target on Bruker from $50.00 to $45.00 and set a "neutral" rating on the stock in a research report on Thursday, May 8th. Five analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, Bruker presently has an average rating of "Hold" and a consensus target price of $51.30.

Bruker Stock Performance

Shares of NASDAQ:BRKR traded down $3.88 on Wednesday, hitting $29.35. The company's stock had a trading volume of 18,323,888 shares, compared to its average volume of 2,747,442. Bruker Corporation has a 12 month low of $28.53 and a 12 month high of $72.94. The company has a market capitalization of $4.45 billion, a price-to-earnings ratio of 56.44, a price-to-earnings-growth ratio of 2.79 and a beta of 1.21. The stock's 50-day moving average is $37.59 and its two-hundred day moving average is $39.96. The company has a debt-to-equity ratio of 1.31, a quick ratio of 0.70 and a current ratio of 1.61.

Bruker (NASDAQ:BRKR - Get Free Report) last released its quarterly earnings results on Monday, August 4th. The medical research company reported $0.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.33 by ($0.01). Bruker had a return on equity of 17.89% and a net margin of 2.31%.The business had revenue of $797.40 million during the quarter, compared to the consensus estimate of $811.17 million. During the same period in the previous year, the company posted $0.52 EPS. The company's revenue for the quarter was down .4% compared to the same quarter last year. Bruker has set its FY 2025 guidance at 1.950-2.050 EPS. On average, equities research analysts forecast that Bruker Corporation will post 2.69 EPS for the current year.

Bruker Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 3rd. Stockholders of record on Tuesday, September 23rd will be paid a $0.05 dividend. The ex-dividend date of this dividend is Tuesday, September 23rd. This represents a $0.20 annualized dividend and a dividend yield of 0.7%. Bruker's dividend payout ratio is presently 38.46%.

Bruker Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.